MRNA
Moderna, Inc.
49.20
3 x 49.05
6 x 49.38
bid
ask
-
0.83
1.66%
5 @ 04:00 PM
49.30 +0.10 (0.20%)
Ytd 66.84%
1y 77.49%
48.11
day range
50.51
22.36
52 week range
57.80
Open 48.15 Prev Close 50.03 Low 48.11 High 50.51 Mkt Cap 19.51B
Vol 4.61M Avg Vol 11.04M EPS -7.26 P/E N/A Forward P/E -10.59
Beta 1.34 Short Ratio 6.35 Inst. Own 77.12% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 04-30 50-d Avg 49.09 200-d Avg 33.54 1yr Est 44.90
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 0 N/A N/A N/A
2026-02-13 2025-12 0 N/A 0.49 18.85%
2025-11-06 2025-09 0 N/A 1.64 76.28%
2025-08-01 2025-06 0 N/A 0.86 28.76%
2025-05-01 2025-03 0 N/A 0.4 13.70%
2025-02-14 2024-12 0 N/A 0.19 7.06%
Upgrade / Downgrade
Date Firm Action From To
2026-04-02 Barclays Upgrade Equal-Weight Equal-Weight
2026-02-23 Piper Sandler Upgrade Overweight Overweight
2026-02-17 Goldman Sachs Upgrade Neutral Neutral
2026-02-17 RBC Capital Upgrade Sector Perform Sector Perform
2026-02-17 Evercore ISI Group Upgrade In-Line In-Line
2025-12-12 Morgan Stanley Upgrade Equal-Weight Equal-Weight
Profile
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2025-12-10 AFEYAN NOUBAR BOGHOS Director 0.00 Conversion of Exercise of derivative security
2026-02-10 BANCEL STEPHANE J Chief Executive Officer 21.96M Stock Award(Grant)
2024-05-02 BERENSON STEPHEN A. Director 22.20K Conversion of Exercise of derivative security
2026-02-26 HOGE STEPHEN President 1.63M Conversion of Exercise of derivative security
2025-04-29 HORNING SANDRA Director 2.35K Conversion of Exercise of derivative security
2026-03-04 KLINGER SHANNON THYME Officer 65.78K Conversion of Exercise of derivative security
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 41.58M 2.05B 10.53%
2025-12-30 Blackrock Inc. 32.51M 1.60B 8.23%
2025-12-30 FMR, LLC 28.05M 1.38B 7.10%
2025-12-30 BAILLIE GIFFORD & CO 20.58M 1.01B 5.21%
2025-12-30 State Street Corporation 16.37M 805.18M 4.14%
2025-12-30 Capital World Investors 12.83M 631.14M 3.25%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 11.02M 542.31M 2.79%
2025-12-30 GROWTH FUND OF AMERICA 9.52M 468.49M 2.41%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 8.77M 431.43M 2.22%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 7.98M 392.58M 2.02%
2025-11-29 VANGUARD WORLD FUND-Vanguard International Growth Fund 6.20M 305.15M 1.57%
2026-01-30 Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF 5.49M 270.14M 1.39%
Split
Split Date
1 : 10 2017-08-03